3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Sarcoma, Kaposi
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Epstein-Barr Virus Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cyclophosphamide
28
pembrolizumab
22
Bevacizumab
18
Fluorouracil
17
Cisplatin
17
Nivolumab
16
Capecitabine
16
Leucovorin
15
Dexamethasone
14
Carboplatin
13
avelumab
12
Oxaliplatin
12
Radiosurgery
11
Gemcitabine
11
Rituximab
10
Radiotherapy
10
Lenalidomide
10
ALT-803
10
venetoclax
9
fludarabine
9
Taxes
9
Omacor
9
Azacitidine
9
130-nm albumin-bound paclitaxel
9
Paclitaxel
8
Docetaxel
8
Bortezomib
8
fludarabine phosphate
7
Melphalan
7
Irinotecan
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Withdrawn
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn